TABLE 2.

Characteristics of ADR reports of Two DNA Methylation Inhibitors.

	Azacitidine	Decitabine
Number of ADR reports	17,925	5,838
Female	6,298 (35.1%)	2022 (34.6%)
Male	9,905 (55.3%)	3,186 (54.6%)
Unknown	1722 (9.6%)	630 (10.8%)
<18	240 (1.3%)	121 (2.1%)
18–44	734 (4.1%)	441 (7.6%)
45–64	3,290 (18.4%)	1,333 (22.8%)
65–74	5,221 (29.1%)	1728 (29.6%
>75	4,745 (26.5%)	1,331 (22.8%)
Unknown	3,695 (20.6%)	884 (15.1%)
Africa	43 (0.2%)	3 (0.1%)
Americas	5,860 (32.7%)	1741 (29.8%)
Asia	5,594 (31.2%)	3,528 (60.4%)
Europe	5,805 (32.4%)	556 (9.5%)
Oceania	623 (3.5%)	10 (0.2%)
Before 2010	845 (4.7%)	389 (6.7%)
2011	598 (3.3%)	137 (2.3%)
2012	606 (3.4%)	77 (1.3%)
2013	1,131 (6.3%)	92 (1.6%)
2014	1,294 (7.2%)	333 (5.7%)
2015	1,374 (7.7%)	545 (9.3%)
2016	1,332 (7.4%)	585 (10%)
2017	945 (5.3%)	437 (7.5%)
2018	1,076 (6%)	307 (5.3%)
2019	1,212 (6.8%)	444 (7.6%)
2020	1,053 (5.9%)	712 (12.2%)
2021	1,496 (8.3%)	444 (7.6%)
2022	1892 (10.6%)	383 (6.6%)
2023	1993 (11.1%)	560 (9.6%)
2024	1,078 (6%)	393 (6.7%)